https://www.prnewswire.com/news-releases/nuvalent-to-present-new-preclinical-data-for-her2-selective-inhibitor-nvl-330-at-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-302582286.html
Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC...
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
to presentnuvalentnewpreclinicaldata
https://www.edgen.tech/news/post/nuvalent-gets-september-18-pdufa-date-for-zidesamtinib-in-lung-cancer
Nuvalent gets September 18 PDUFA date for zidesamtinib in lung cancer
On May 7, 2026, Nuvalent, Inc. announced its New Drug Application (NDA) for zidesamtinib for advanced ROS1-positive NSCLC is under FDA review with a PDUFA...
lung cancernuvalentgetsseptemberdate
https://www.sahmcapital.com/news/content/nuvalent-submits-fda-nda-for-neladalkib-in-pretreated-alk-positive-lung-cancer-2026-04-07
Nuvalent submits FDA NDA for neladalkib in pretreated ALK-positive lung cancer
Nuvalent submitted a New Drug Application to FDA for neladalkib in TKI pre-treated advanced ALK-positive non-small cell lung cancer. Filing is supported by...
lung cancernuvalentfdandaalk
https://www.heygotrade.com/en/us-stock/nuvl/
Nuvalent, Inc. Class A Common Stock (NUVL) Stock Price Today & Analysis | Buy on Gotrade
Get the latest Nuvalent, Inc. Class A Common Stock (NUVL) stock price and in-depth analysis. Learn how to invest in Nuvalent, Inc. Class A Common Stock stock...
class acommon stocknuvalentincnuvl